

Stuart J Pocock

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8240246/publications.pdf>

Version: 2024-02-01

404
papers

130,144
citations

1238

110
h-index

105

348
g-index

414
all docs

414
docs citations

414
times ranked

108802
citing authors

#	ARTICLE	IF	CITATIONS
1	Efficacy and safety of alirocumab and evolocumab: a systematic review and meta-analysis of randomized controlled trials. <i>European Heart Journal</i> , 2022, 43, e17-e25.	2.2	92
2	Sex differences in mortality after an acute coronary syndrome increase with lower country wealth and higher income inequality. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2022, 75, 392-400.	0.6	5
3	Rationale and design of the pragmatic clinical trial tREatment with Beta-blockers after myOcardial infarction withOut reduced ejection fracTion (REBOOT). <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2022, 8, 291-301.	3.0	19
4	Empagliflozin in the treatment of heart failure with reduced ejection fraction in addition to background therapies and therapeutic combinations (EMPEROR-Reduced): a post-hoc analysis of a randomised, double-blind trial. <i>Lancet Diabetes and Endocrinology</i> , 2022, 10, 35-45.	11.4	29
5	Empagliflozin, Health Status, and Quality of Life in Patients With Heart Failure and Preserved Ejection Fraction: The EMPEROR-Preserved Trial. <i>Circulation</i> , 2022, 145, 184-193.	1.6	106
6	Early benefit with empagliflozin in heart failure with preserved ejection fraction: insights from the EMPEROR-Preserved trial. <i>European Journal of Heart Failure</i> , 2022, 24, 245-248.	7.1	26
7	Impact of anaemia and the effect of empagliflozin in heart failure with reduced ejection fraction: findings from the EMPEROR-Reduced. <i>European Journal of Heart Failure</i> , 2022, 24, 708-715.	7.1	32
8	Ticagrelor Monotherapy After PCI in High-Risk Patients With Prior MI. <i>JACC: Cardiovascular Interventions</i> , 2022, 15, 282-293.	2.9	6
9	Effect of continuing versus stopping pre-stroke antihypertensive agents within 12h on outcome after stroke: A subgroup analysis of the efficacy of nitric oxide in stroke (ENOS) trial. <i>EClinicalMedicine</i> , 2022, 44, 101274.	7.1	1
10	The effect of empagliflozin on the total burden of cardiovascular and hospitalization events in the Asian and non-Asian populations of the EMPEROR-OUTCOME trial of patients with type 2 diabetes and cardiovascular disease. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 662-674.	4.4	15
11	Effect of empagliflozin in patients with heart failure across the spectrum of left ventricular ejection fraction. <i>European Heart Journal</i> , 2022, 43, 416-424.	2.2	144
12	Ticagrelor monotherapy after PCI in patients with concomitant diabetes mellitus and chronic kidney disease: TWILIGHT DM-CKD. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2022, 8, 707-716.	3.0	5
13	Safety and efficacy of ticagrelor monotherapy according to drug-eluting stent type: the TWILIGHT-STENT study. <i>EuroIntervention</i> , 2022, 17, 1330-1339.	3.2	5
14	Mineralocorticoid Receptor Antagonists and Empagliflozin in Patients With Heart Failure and Preserved Ejection Fraction. <i>Journal of the American College of Cardiology</i> , 2022, 79, 1129-1137.	2.8	36
15	Covariate Adjustment in Cardiovascular Randomized Controlled Trials. <i>JACC: Heart Failure</i> , 2022, 10, 297-305.	4.1	2
16	Long-term efficacy and safety of renal denervation in the presence of antihypertensive drugs (SPYRAL). <i>Journal of the American College of Cardiology</i> , 2022, 79, 1129-1137.	18.7	114
17	Empagliflozin and serum potassium in heart failure: an analysis from EMPEROR-Pooled. <i>European Heart Journal</i> , 2022, 43, 2984-2993.	2.2	30
18	Biomarker-driven prognostic models in chronic heart failure with preserved ejection fraction: the EMPEROR-Preserved trial. <i>European Journal of Heart Failure</i> , 2022, 24, 1869-1878.	7.1	21

#	ARTICLE	IF	CITATIONS
19	Uric acid and sodium-glucose cotransporter-2 inhibition with empagliflozin in heart failure with reduced ejection fraction: the EMPEROR-reduced trial. <i>European Heart Journal</i> , 2022, 43, 3435-3446.	2.2	39
20	Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): Explanation and Elaboration. <i>Voprosy Sovremennoi Pediatrii - Current Pediatrics</i> , 2022, 21, 173-208.	0.4	2
21	Relationship between nitrate headache and outcome in patients with acute stroke: results from the efficacy of nitric oxide in stroke (ENOS) trial. <i>Stroke and Vascular Neurology</i> , 2021, 6, 180-186.	3.3	2
22	The age of randomized clinical trials: three important aspects of randomized clinical trials in cardiovascular pharmacotherapy with examples from lipid, diabetes, and antithrombotic trials. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021, 7, 453-459.	3.0	5
23	Effect of Empagliflozin on the Clinical Stability of Patients With Heart Failure and a Reduced Ejection Fraction. <i>Circulation</i> , 2021, 143, 326-336.	1.6	222
24	Cardiac and Kidney Benefits of Empagliflozin in Heart Failure Across the Spectrum of Kidney Function. <i>Circulation</i> , 2021, 143, 310-321.	1.6	168
25	Rationale and design of ApoA-I Event Reducing in Ischemic Syndromes II (AEGIS-II): A phase 3, multicenter, double-blind, randomized, placebo-controlled, parallel-group study to investigate the efficacy and safety of CSL112 in subjects after acute myocardial infarction. <i>American Heart Journal</i> , 2021, 231, 121-127.	2.7	60
26	Long-term antiplatelet therapy in medically managed non-ST-segment elevation acute coronary syndromes: The EPICOR Asia study. <i>International Journal of Cardiology</i> , 2021, 327, 19-24.	1.7	1
27	Effect of Empagliflozin on Cardiovascular and Renal Outcomes in Patients With Heart Failure by Baseline Diabetes Status. <i>Circulation</i> , 2021, 143, 337-349.	1.6	217
28	Global patterns of comprehensive cardiovascular risk factor control in patients with type 2 diabetes mellitus: Insights from the <scp>DISCOVER</scp> study. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 39-48.	4.4	11
29	Influence of neprilysin inhibition on the efficacy and safety of empagliflozin in patients with chronic heart failure and a reduced ejection fraction: the EMPEROR-Reduced trial. <i>European Heart Journal</i> , 2021, 42, 671-680.	2.2	96
30	Empagliflozin and health-related quality of life outcomes in patients with heart failure with reduced ejection fraction: the EMPEROR-Reduced trial. <i>European Heart Journal</i> , 2021, 42, 1203-1212.	2.2	114
31	Number of Antithrombotic Drugs Used Early and In-hospital Outcomes in Acute Coronary Syndromes. <i>Journal of Cardiovascular Translational Research</i> , 2021, 14, 790-798.	2.4	1
32	Health-related quality of life 1â€“3 years post-myocardial infarction: its impact on prognosis. <i>Open Heart</i> , 2021, 8, e001499.	2.3	18
33	Ticagrelor Monotherapy Versus Dual-Antiplatelet Therapy After PCI. <i>JACC: Cardiovascular Interventions</i> , 2021, 14, 444-456.	2.9	27
34	Long-Term Antithrombotic Therapy and Clinical Outcomes in Patients with Acute Coronary Syndrome and Renal Impairment: Insights from EPICOR and EPICOR Asia. <i>American Journal of Cardiovascular Drugs</i> , 2021, 21, 471-482.	2.2	1
35	Synergistic Impact of Systolic Blood Pressure and Perfusion Status on Mortality in Acute Heart Failure. <i>Circulation: Heart Failure</i> , 2021, 14, e007347.	3.9	17
36	Interplay of Mineralocorticoid Receptor Antagonists and Empagliflozin in Heart Failure. <i>Journal of the American College of Cardiology</i> , 2021, 77, 1397-1407.	2.8	105

#	ARTICLE	IF	CITATIONS
37	Empagliflozin in Patients With Heart Failure, Reduced Ejection Fraction, and Volume Overload. Journal of the American College of Cardiology, 2021, 77, 1381-1392.	2.8	94
38	Blood pressure reduction and antihypertensive treatment choice: A post hoc analysis of the SPRINT trial. Clinical Cardiology, 2021, 44, 665-674.	1.8	3
39	Prioritised endpoints for device-based hypertension trials: the win ratio methodology. EuroIntervention, 2021, 16, e1496-e1502.	3.2	12
40	Assessing the Risks of Bleeding vs Thrombotic Events in Patients at High Bleeding Risk After Coronary Stent Implantation. JAMA Cardiology, 2021, 6, 410.	6.1	52
41	Impact of Insulin Treatment on the Effect of Eplerenone: Insights From the EMPHASIS-HF Trial. Circulation: Heart Failure, 2021, 14, e008075.	3.9	3
42	Regional and ethnic influences on the response to empagliflozin in patients with heart failure and a reduced ejection fraction: the EMPEROR-Reduced trial. European Heart Journal, 2021, 42, 4442-4451.	2.2	38
43	Concentration-dependent clinical and prognostic importance of high-sensitivity cardiac troponin T in heart failure and a reduced ejection fraction and the influence of empagliflozin: the EMPEROR-Reduced trial. European Journal of Heart Failure, 2021, 23, 1529-1538.	7.1	30
44	Changes in Plasma Renin Activity After Renal Artery Sympathetic Denervation. Journal of the American College of Cardiology, 2021, 77, 2909-2919.	2.8	63
45	Lowering systolic blood pressure to 120 mmHg or The Lancet's true grit. European Heart Journal, 2021, 42, 2052-2059.	2.2	1
46	Subgroup analyses in randomized clinical trials: value and limitations. Review #3 on important aspects of randomized clinical trials in cardiovascular pharmacotherapy. European Heart Journal - Cardiovascular Pharmacotherapy, 2021, , .	3.0	6
47	Implications of Biomarker Discordance After Coronary Artery Revascularization. Journal of the American College of Cardiology, 2021, 77, 2978-2980.	2.8	1
48	Sex-Based Differences in Bleeding Risk After Percutaneous Coronary Intervention and Implications for the Academic Research Consortium High Bleeding Risk Criteria. Journal of the American Heart Association, 2021, 10, e021965.	3.7	23
49	Impact of Age on the Safety and Efficacy of Ticagrelor Monotherapy in Patients Undergoing PCI. JACC: Cardiovascular Interventions, 2021, 14, 1434-1446.	2.9	13
50	Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): Explanation and Elaboration. Translation to Russian. Digital Diagnostics, 2021, 2, 119-169.	0.6	7
51	Effect of Empagliflozin on Worsening Heart Failure Events in Patients With Heart Failure and Preserved Ejection Fraction: EMPEROR-Preserved Trial. Circulation, 2021, 144, 1284-1294.	1.6	195
52	Empagliflozin and Major Renal Outcomes in Heart Failure. New England Journal of Medicine, 2021, 385, 1531-1533.	27.0	78
53	Influenza Vaccination After Myocardial Infarction: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial. Circulation, 2021, 144, 1476-1484.	1.6	121
54	Ticagrelor monotherapy in patients with chronic kidney disease undergoing percutaneous coronary intervention: TWILIGHT-CKD. European Heart Journal, 2021, 42, 4683-4693.	2.2	18

#	ARTICLE	IF	CITATIONS
55	Novel biomarker-driven prognostic models to predict morbidity and mortality in chronic heart failure: the EMPEROR-Reduced trial. <i>European Heart Journal</i> , 2021, 42, 4455-4464.	2.2	33
56	Primary and Secondary Outcome Reporting in Randomized Trials. <i>Journal of the American College of Cardiology</i> , 2021, 78, 827-839.	2.8	28
57	Influence of endpoint definitions on the effect of empagliflozin on major renal outcomes in the <scp>EMPERORâ€Preserved</scp> trial. <i>European Journal of Heart Failure</i> , 2021, 23, 1798-1799.	7.1	21
58	Effect of Heart Rate on the Outcome of Renal Denervation in Patients With Uncontrolled Hypertension. <i>Journal of the American College of Cardiology</i> , 2021, 78, 1028-1038.	2.8	27
59	A re-examination of the SPYRAL HTN-OFF MED Pivotal trial with respect to the underlying model assumptions. <i>Contemporary Clinical Trials Communications</i> , 2021, 23, 100818.	1.1	3
60	Sex Differences Among Patients With High Risk Receiving Ticagrelor With or Without Aspirin After Percutaneous Coronary Intervention. <i>JAMA Cardiology</i> , 2021, 6, 1032.	6.1	27
61	Prognostic Importance of NT-proBNP and Effect of Empagliflozin in the EMPEROR-Reduced Trial. <i>Journal of the American College of Cardiology</i> , 2021, 78, 1321-1332.	2.8	55
62	Empagliflozin Improves Cardiovascular and Renal Outcomes in Heart Failure Irrespective of Systolic Blood Pressure. <i>Journal of the American College of Cardiology</i> , 2021, 78, 1337-1348.	2.8	52
63	Ticagrelor monotherapy in patients at high bleeding risk undergoing percutaneous coronary intervention: TWILIGHT-HBR. <i>European Heart Journal</i> , 2021, 42, 4624-4634.	2.2	54
64	The effect of intravenous ferric carboxymaltose on health-related quality of life in iron-deficient patients with acute heart failure: the results of the AFFIRM-AHF study. <i>European Heart Journal</i> , 2021, 42, 3011-3020.	2.2	71
65	Impact of clinical presentation on bleeding risk after percutaneous coronary intervention and implications for the ARC-HBR definition. <i>EuroIntervention</i> , 2021, 17, e898-e909.	3.2	45
66	Statistical reanalysis of vascular event outcomes in primary and secondary vascular prevention trials. <i>BMC Medical Research Methodology</i> , 2021, 21, 218.	3.1	4
67	The Clinical outcomes, healthcare resource utilization, and related costs (COHERENT) model. Application in heart failure patients. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2021, , .	0.6	2
68	Determinants of long-term dual antiplatelet therapy use in post myocardial infarction patients: Insights from the TIGRIS registry. <i>Journal of Cardiology</i> , 2021, , .	1.9	2
69	A contemporary simple risk score for prediction of contrast-associated acute kidney injury after percutaneous coronary intervention: derivation and validation from an observational registry. <i>Lancet, The</i> , 2021, 398, 1974-1983.	13.7	69
70	291 Ticagrelor monotherapy after percutaneous coronary intervention in high-risk patients with prior myocardial infarction: a prespecified twilight substudy. <i>European Heart Journal Supplements</i> , 2021, 23, .	0.1	0
71	Atrial fibrillation and clinical outcomes 1 to 3 years after myocardial infarction. <i>Open Heart</i> , 2021, 8, e001726.	2.3	5
72	Incidence, predictors and impact of stroke on mortality among patients with acute coronary syndromes following percutaneous coronary interventionâ€Results from the PROMETHEUS registry. <i>Catheterization and Cardiovascular Interventions</i> , 2020, 95, 885-892.	1.7	5

#	ARTICLE	IF	CITATIONS
73	Effect of hospital volume on 90-day mortality after radical cystectomy for bladder cancer in Spain. <i>World Journal of Urology</i> , 2020, 38, 1221-1228.	2.2	9
74	Predicting risk of cardiovascular events 1 to 3 years post-myocardial infarction using a global registry. <i>Clinical Cardiology</i> , 2020, 43, 24-32.	1.8	18
75	Glycaemic control in patients with type 2 diabetes initiating second-line therapy: Results from the global DISCOVER study programme. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 66-78.	4.4	20
76	Cardiovascular risk associated with serum potassium in the context of mineralocorticoid receptor antagonist use in patients with heart failure and left ventricular dysfunction. <i>European Journal of Heart Failure</i> , 2020, 22, 1402-1411.	7.1	19
77	Estimating the Lifetime Benefits of Treatments for Heart Failure. <i>JACC: Heart Failure</i> , 2020, 8, 984-995.	4.1	15
78	Ticagrelor alone vs. ticagrelor plus aspirin following percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndromes: TWILIGHT-ACS. <i>European Heart Journal</i> , 2020, 41, 3533-3545.	2.2	93
79	Validation of high bleeding risk criteria and definition as proposed by the academic research consortium for high bleeding risk. <i>European Heart Journal</i> , 2020, 41, 3743-3749.	2.2	89
80	Design of a prospective patient-level pooled analysis of two parallel trials of empagliflozin in patients with established heart failure. <i>European Journal of Heart Failure</i> , 2020, 22, 2393-2398.	7.1	19
81	Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial. <i>Lancet, The</i> , 2020, 396, 1895-1904.	13.7	425
82	Baseline characteristics of patients with heart failure with preserved ejection fraction in the EMPEROR-Preserved trial. <i>European Journal of Heart Failure</i> , 2020, 22, 2383-2392.	7.1	93
83	Effects of empagliflozin on first and recurrent clinical events in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a secondary analysis of the EMPA-REG OUTCOME trial. <i>Lancet Diabetes and Endocrinology</i> , 2020, 8, 949-959.	11.4	41
84	Metformin discontinuation in patients beginning second-line glucose-lowering therapy: results from the global observational DISCOVER study programme. <i>BMJ Open</i> , 2020, 10, e034613.	1.9	3
85	Implications of Alternative Definitions of Peri-Procedural Myocardial Infarction After Coronary Revascularization. <i>Journal of the American College of Cardiology</i> , 2020, 76, 1609-1621.	2.8	75
86	Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. <i>New England Journal of Medicine</i> , 2020, 383, 1413-1424.	27.0	2,821
87	SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials. <i>Lancet, The</i> , 2020, 396, 819-829.	13.7	816
88	Trial Design Principles for Patients at High Bleeding Risk Undergoing PCI. <i>Journal of the American College of Cardiology</i> , 2020, 76, 1468-1483.	2.8	35
89	The win ratio approach for composite endpoints: practical guidance based on previous experience. <i>European Heart Journal</i> , 2020, 41, 4391-4399.	2.2	72
90	Diabetes association with self-reported health, resource utilization, and prognosis post-myocardial infarction. <i>Clinical Cardiology</i> , 2020, 43, 1352-1361.	1.8	3

#	ARTICLE	IF	CITATIONS
91	Cardiovascular Risk Reduction With Liraglutide: An Exploratory Mediation Analysis of the LEADER Trial. <i>Diabetes Care</i> , 2020, 43, 1546-1552.	8.6	92
92	Global Approach to High Bleeding Risk Patients With Polymer-Free Drug-Coated Coronary Stents. <i>Circulation: Cardiovascular Interventions</i> , 2020, 13, e008603.	3.9	28
93	Impact of tricuspid regurgitation on survival in patients with heart failure: a large electronic health record patient-level database analysis. <i>European Journal of Heart Failure</i> , 2020, 22, 1803-1813.	7.1	75
94	Two-year outcomes post-discharge in Asian patients with acute coronary syndrome: Findings from the EPICOR Asia study. <i>International Journal of Cardiology</i> , 2020, 315, 1-8.	1.7	6
95	Spironolactone dose in heart failure with preserved ejection fraction: findings from TOPCAT. <i>European Journal of Heart Failure</i> , 2020, 22, 1615-1624.	7.1	24
96	Conducting clinical trials in heart failure during (and after) the COVID-19 pandemic: an Expert Consensus Position Paper from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). <i>European Heart Journal</i> , 2020, 41, 2109-2117.	2.2	65
97	Antithrombotic management and long-term outcomes following percutaneous coronary intervention for acute coronary syndrome in Asia. <i>International Journal of Cardiology</i> , 2020, 310, 16-22.	1.7	13
98	Efficacy of catheter-based renal denervation in the absence of antihypertensive medications (SPYRAL) Tj ETQq0 0 0 rgBT /Overlock 10 TF 1444-1451.	13.7	351
99	Bleeding Risk, Dual Antiplatelet Therapy Cessation, and Adverse Events After Percutaneous Coronary Intervention. <i>Circulation: Cardiovascular Interventions</i> , 2020, 13, e008226.	3.9	21
100	A Framework for Methodological Choice and Evidence Assessment for Studies Using External Comparators from Real-World Data. <i>Drug Safety</i> , 2020, 43, 623-633.	3.2	26
101	Long-term antithrombotic management patterns in Asian patients with acute coronary syndrome: 2-year observations from the EPICOR Asia study. <i>Clinical Cardiology</i> , 2020, 43, 999-1008.	1.8	6
102	Rationale and design of two randomized sham-controlled trials of catheter-based renal denervation in subjects with uncontrolled hypertension in the absence (SPYRAL HTN-OFF MED Pivotal) and presence (SPYRAL HTN-ON MED Expansion) of antihypertensive medications: a novel approach using Bayesian design. <i>Clinical Research in Cardiology</i> , 2020, 109, 289-302.	3.3	28
103	Stent-Related Adverse Events >1 Year After Percutaneous Coronary Intervention. <i>Journal of the American College of Cardiology</i> , 2020, 75, 590-604.	2.8	160
104	Two-year outcomes among stable high-risk patients following acute MI. Insights from a global registry in 25 countries. <i>International Journal of Cardiology</i> , 2020, 311, 7-14.	1.7	9
105	Mortality After Repeat Revascularization Following PCI or CABG for Left Main Disease. <i>JACC: Cardiovascular Interventions</i> , 2020, 13, 375-387.	2.9	55
106	Prolonged dual antiplatelet therapy in patients with non-ST-segment elevation myocardial infarction: 2-year findings from EPICOR Asia. <i>Clinical Cardiology</i> , 2020, 43, 346-354.	1.8	4
107	Prasugrel use and clinical outcomes by age among patients undergoing PCI for acute coronary syndrome: from the PROMETHEUS study. <i>Clinical Research in Cardiology</i> , 2020, 109, 725-734.	3.3	5
108	1-Year Clinical Outcomes of All Comers Treated With 2 Bioresorbable Polymer-Coated Sirolimus-Eluting Stents. <i>JACC: Cardiovascular Interventions</i> , 2020, 13, 820-830.	2.9	10

#	ARTICLE	IF	CITATIONS
109	Yoga-Based Cardiac Rehabilitation After Acute Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2020, 75, 1551-1561.	2.8	55
110	Ticagrelor With or Without Aspirin in High-Risk Patients With Diabetes Mellitus Undergoing Percutaneous Coronary Intervention. <i>Journal of the American College of Cardiology</i> , 2020, 75, 2403-2413.	2.8	60
111	Ticagrelor With or Without Aspirin After Complex APCI. <i>Journal of the American College of Cardiology</i> , 2020, 75, 2414-2424.	2.8	122
112	Use of the Win Ratio in Cardiovascular Trials. <i>JACC: Heart Failure</i> , 2020, 8, 441-450.	4.1	34
113	The Usefulness of the MEESI Score for Risk Stratification of Patients With Acute Heart Failure at the Emergency Department. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2019, 72, 198-207.	0.6	8
114	Geographical Variations in Patterns of DAPT Cessation and Two-Year PCI Outcomes: Insights from the PARIS Registry. <i>Thrombosis and Haemostasis</i> , 2019, 119, 1704-1711.	3.4	2
115	Evaluation of the effect of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality of patients with chronic heart failure and a reduced ejection fraction: rationale for and design of the EMPEROR-Reduced trial. <i>European Journal of Heart Failure</i> , 2019, 21, 1270-1278.	7.1	155
116	Treatment patterns and associated factors in 14 668 people with type 2 diabetes initiating a second-line therapy: Results from the global DISCOVER study programme. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 2474-2485.	4.4	36
117	Nonproportional Hazards for Time-to-Event Outcomes in Clinical Trials. <i>Journal of the American College of Cardiology</i> , 2019, 74, 2102-2112.	2.8	45
118	In-Hospital Coronary Revascularization Rates and Post-Discharge Mortality Risk in Non-ST-Segment Elevation Acute Coronary Syndrome. <i>Journal of the American College of Cardiology</i> , 2019, 74, 1454-1461.	2.8	37
119	Five-Year Outcomes after PCI or CABG for Left Main Coronary Disease. <i>New England Journal of Medicine</i> , 2019, 381, 1820-1830.	27.0	523
120	Ticagrelor with or without Aspirin in High-Risk Patients after PCI. <i>New England Journal of Medicine</i> , 2019, 381, 2032-2042.	27.0	683
121	Raised blood pressure and risk of dementia. <i>European Heart Journal</i> , 2019, 40, 785-786.	2.2	5
122	Effect of Barthel Index on the Risk of Thirty-Day Mortality in Patients With Acute Heart Failure Attending the Emergency Department: A Cohort Study of Nine Thousand Ninety-Eight Patients From the Epidemiology of Acute Heart Failure in Emergency Departments Registry. <i>Annals of Emergency Medicine</i> , 2019, 73, 589-598.	0.6	22
123	Analysis of How Emergency Physicians' Decisions to Hospitalize or Discharge Patients With Acute Heart Failure Match the Clinical Risk Categories of the MEESI-AHF Scale. <i>Annals of Emergency Medicine</i> , 2019, 74, 204-215.	0.6	35
124	Development of a Yoga-Based Cardiac Rehabilitation (Yoga-CaRe) Programme for Secondary Prevention of Myocardial Infarction. <i>Evidence-based Complementary and Alternative Medicine</i> , 2019, 2019, 1-7.	1.2	12
125	Effects of Icosapent Ethyl on Total Ischemic Events. <i>Journal of the American College of Cardiology</i> , 2019, 73, 2791-2802.	2.8	208
126	Defining high bleeding risk in patients undergoing percutaneous coronary intervention: a consensus document from the Academic Research Consortium for High Bleeding Risk. <i>European Heart Journal</i> , 2019, 40, 2632-2653.	2.2	335

#	ARTICLE	IF	CITATIONS
127	Defining High Bleeding Risk in Patients Undergoing Percutaneous Coronary Intervention. <i>Circulation</i> , 2019, 140, 240-261.	1.6	428
128	Dual-Antiplatelet Therapy Cessation and Cardiovascular Risk in Relation to Age. <i>JACC: Cardiovascular Interventions</i> , 2019, 12, 983-992.	2.9	12
129	Influence of Baseline Anemia on Dual Antiplatelet Therapy Cessation and Risk of Adverse Events After Percutaneous Coronary Intervention. <i>Circulation: Cardiovascular Interventions</i> , 2019, 12, e007133.	3.9	17
130	Statistical Appraisal of Recent Clinical Trials in Cardiology. <i>Journal of the American College of Cardiology</i> , 2019, 73, 2740-2755.	2.8	24
131	Are risk minimization measures for approved drugs in Europe effective? A systematic review. <i>Expert Opinion on Drug Safety</i> , 2019, 18, 443-454.	2.4	21
132	Treatment of type 2 diabetes mellitus worldwide: Baseline patient characteristics in the global DISCOVER study. <i>Diabetes Research and Clinical Practice</i> , 2019, 151, 20-32.	2.8	63
133	Transcatheter Aortic-Valve Replacement with a Balloon-Expandable Valve in Low-Risk Patients. <i>New England Journal of Medicine</i> , 2019, 380, 1695-1705.	27.0	3,312
134	Associations between use of prasugrel vs clopidogrel and outcomes by type of acute coronary syndrome: an analysis from the PROMETHEUS registry. <i>Journal of Thrombosis and Thrombolysis</i> , 2019, 48, 42-51.	2.1	5
135	Bypass Surgery or Stenting for Left Main Coronary Artery Disease in Patients With Diabetes. <i>Journal of the American College of Cardiology</i> , 2019, 73, 1616-1628.	2.8	60
136	Renal function stratified dose comparisons of eplerenone versus placebo in the EMPHASIS-HF trial. <i>European Journal of Heart Failure</i> , 2019, 21, 345-351.	7.1	43
137	External Validation of the MEESI Acute Heart Failure Risk Score. <i>Annals of Internal Medicine</i> , 2019, 170, 248.	3.9	40
138	MRAs in Elderly HF Patients. <i>JACC: Heart Failure</i> , 2019, 7, 1012-1021.	4.1	33
139	Associations between change in blood pressure and functional outcome, early events and death. <i>Journal of Hypertension</i> , 2019, 37, 2104-2109.	0.5	3
140	Impact of eplerenone on major cardiovascular outcomes in patients with systolic heart failure according to baseline heart rate. <i>Clinical Research in Cardiology</i> , 2019, 108, 806-814.	3.3	5
141	Predictors of all-cause mortality and ischemic events within and beyond 1 year after an acute coronary syndrome: Results from the EPICOR registry. <i>Clinical Cardiology</i> , 2019, 42, 111-119.	1.8	37
142	Tailoring Antiplatelet Therapy Intensity to Ischemic and Bleeding Risk. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2019, 12, e004945.	2.2	7
143	Ambulatory heart rate reduction after catheter-based renal denervation in hypertensive patients not receiving anti-hypertensive medications: data from SPYRAL HTN-OFF MED, a randomized, sham-controlled, proof-of-concept trial. <i>European Heart Journal</i> , 2019, 40, 743-751.	2.2	70
144	Patterns and Impact of Dual Antiplatelet Cessation on Cardiovascular Risk After Percutaneous Coronary Intervention in Patients With Acute Coronary Syndromes. <i>American Journal of Cardiology</i> , 2019, 123, 709-716.	1.6	9

#	ARTICLE	IF	CITATIONS
145	Effectiveness and cost-effectiveness of a Yoga-based Cardiac Rehabilitation (Yoga-CaRe) program following acute myocardial infarction: Study rationale and design of a multi-center randomized controlled trial. <i>International Journal of Cardiology</i> , 2019, 280, 14-18.	1.7	21
146	Use of prasugrel and clinical outcomes in African-American patients treated with percutaneous coronary intervention for acute coronary syndromes. <i>Catheterization and Cardiovascular Interventions</i> , 2019, 94, 53-60.	1.7	2
147	Response by Claggett et al to Letter Regarding Article, "Comparison of Time-to-First Event and Recurrent-Event Methods in Randomized Clinical Trials". <i>Circulation</i> , 2019, 139, 422-423.	1.6	0
148	The prevalence, predictors and outcomes of guideline-directed medical therapy in patients with acute myocardial infarction undergoing PCI, an analysis from the PROMETHEUS registry. <i>Catheterization and Cardiovascular Interventions</i> , 2019, 93, E112-E119.	1.7	16
149	Use of prasugrel vs clopidogrel and outcomes in patients with and without diabetes mellitus presenting with acute coronary syndrome undergoing percutaneous coronary intervention. <i>International Journal of Cardiology</i> , 2019, 275, 31-35.	1.7	12
150	Health-related quality of life in people with type 2 diabetes participating in the LEADER trial. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 525-532.	4.4	21
151	Predicting two-year mortality from discharge after acute coronary syndrome: An internationally-based risk score. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2019, 8, 727-737.	1.0	33
152	Ambulance-delivered transdermal glyceryl trinitrate versus sham for ultra-acute stroke: Rationale, design and protocol for the Rapid Intervention with Glyceryl trinitrate in Hypertensive stroke Trial-2 (RIGHT-2) trial (ISRCTN26986053). <i>International Journal of Stroke</i> , 2019, 14, 191-206.	5.9	20
153	Impact of known or new-onset atrial fibrillation on 2-year cardiovascular event rate in patients with acute coronary syndromes: results from the prospective EPICOR Registry. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2019, 8, 121-129.	1.0	31
154	Tranexamic acid to improve functional status in adults with spontaneous intracerebral haemorrhage: the TICH-2 RCT. <i>Health Technology Assessment</i> , 2019, 23, 1-48.	2.8	17
155	Long-Term Outcome of Acute Coronary Syndromes in Patients on Chronic Oral Anticoagulants: Data from the EPICOR Study. <i>Current Vascular Pharmacology</i> , 2019, 18, 92-99.	1.7	0
156	Patients with acute heart failure discharged from the emergency department and classified as low risk by the MEESI score (multiple risk estimate based on the Spanish emergency department scale): prevalence of adverse events and predictability. <i>Emergencias</i> , 2019, 31, 5-14.	0.6	24
157	Regional variations in hospital management and post-discharge mortality in patients with non-ST-segment elevation acute coronary syndrome. <i>Clinical Research in Cardiology</i> , 2018, 107, 836-844.	3.3	34
158	Associations Between Complex PCI and Prasugrel or Clopidogrel Use in Patients With Acute Coronary Syndrome Who Undergo PCI: From the PROMETHEUS Study. <i>Canadian Journal of Cardiology</i> , 2018, 34, 319-329.	1.7	22
159	Antiplatelet therapy with aspirin, clopidogrel, and dipyridamole versus clopidogrel alone or aspirin and dipyridamole in patients with acute cerebral ischaemia (TARDIS): a randomised, open-label, phase 3 superiority trial. <i>Lancet</i> , The, 2018, 391, 850-859.	13.7	125
160	Comparison of Time-to-First Event and Recurrent-Event Methods in Randomized Clinical Trials. <i>Circulation</i> , 2018, 138, 570-577.	1.6	66
161	Incidence, Patterns, and Impact of Dual Antiplatelet Therapy Cessation Among Patients With and Without Chronic Kidney Disease Undergoing Percutaneous Coronary Intervention. <i>Circulation: Cardiovascular Interventions</i> , 2018, 11, e006144.	3.9	24
162	Ever-Pregnant Female Blood Donors and Mortality Risk in Male Recipients. <i>JAMA - Journal of the American Medical Association</i> , 2018, 319, 1048.	7.4	4

#	ARTICLE	IF	CITATIONS
163	Effects of ferric carboxymaltose on hospitalisations and mortality rates in iron-deficient heart failure patients: an individual patient data meta-analysis. <i>European Journal of Heart Failure</i> , 2018, 20, 125-133.	7.1	317
164	Individualizing treatment choices in the systolic blood pressure intervention trial. <i>Journal of Hypertension</i> , 2018, 36, 428-435.	0.5	7
165	Therapeutic inertia in the treatment of hyperglycaemia in patients with type 2 diabetes: A systematic review. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 427-437.	4.4	247
166	Contribution of cardiac and extra-cardiac disease burden to risk of cardiovascular outcomes varies by ejection fraction in heart failure. <i>European Journal of Heart Failure</i> , 2018, 20, 504-510.	7.1	52
167	Patterns of glycaemic control in patients with type 2 diabetes mellitus initiating second-line therapy after metformin monotherapy: retrospective data for 10%256 individuals from the United Kingdom and Germany. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 389-399.	4.4	38
168	Statistical analysis plan for the "Rapid Intervention with Glyceryl trinitrate in Hypertensive stroke Trial-2 (RIGHT-2)". <i>European Stroke Journal</i> , 2018, 3, 193-196.	5.5	8
169	Central adjudication of serious adverse events did not affect trial's safety results: Data from the Efficacy of Nitric Oxide in Stroke (ENOS) trial. <i>PLoS ONE</i> , 2018, 13, e0208142.	2.5	6
170	Central masked adjudication of stroke diagnosis at trial entry offered no advantage over diagnosis by local clinicians: Secondary analysis and simulation. <i>Contemporary Clinical Trials Communications</i> , 2018, 12, 176-181.	1.1	5
171	Vascular complications in patients with type 2 diabetes: prevalence and associated factors in 38 countries (the DISCOVER study program). <i>Cardiovascular Diabetology</i> , 2018, 17, 150.	6.8	149
172	Effect of renal denervation on blood pressure in the presence of antihypertensive drugs: 6-month efficacy and safety results from the SPYRAL HTN-ON MED proof-of-concept randomised trial. <i>Lancet, The</i> , 2018, 391, 2346-2355.	13.7	597
173	Tranexamic acid for hyperacute primary IntraCerebral Haemorrhage (TICH-2): an international randomised, placebo-controlled, phase 3 superiority trial. <i>Lancet, The</i> , 2018, 391, 2107-2115.	13.7	309
174	Percutaneous coronary intervention for stable angina in ORBITA. <i>Lancet, The</i> , 2018, 392, 26-27.	13.7	0
175	Left Main Revascularization With PCI or CABG in Patients With Chronic Kidney Disease. <i>Journal of the American College of Cardiology</i> , 2018, 72, 754-765.	2.8	59
176	Predictors of high-cost hospitalization in the treatment of acute coronary syndrome in Asia: findings from EPICOR Asia. <i>BMC Cardiovascular Disorders</i> , 2018, 18, 139.	1.7	11
177	Changes in HbA1c and weight, and treatment persistence, over the 18 months following initiation of second-line therapy in patients with type 2 diabetes: results from the United Kingdom Clinical Practice Research Datalink. <i>BMC Medicine</i> , 2018, 16, 116.	5.5	36
178	Critical Appraisal of the 2018 ACC Scientific Sessions Late-Breaking Trials From a Statistician's Perspective. <i>Journal of the American College of Cardiology</i> , 2018, 71, 2957-2969.	2.8	22
179	Long-term mortality after blood pressure-lowering and lipid-lowering treatment in patients with hypertension in the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) Legacy study: 16-year follow-up results of a randomised factorial trial. <i>Lancet, The</i> , 2018, 392, 1127-1137.	13.7	87
180	Dual Antiplatelet Therapy Cessation and Adverse Events After Drug-Eluting Stent Implantation in Patients at High Risk for Atherothrombosis (from the PARIS Registry). <i>American Journal of Cardiology</i> , 2018, 122, 1638-1646.	1.6	19

#	ARTICLE	IF	CITATIONS
181	Predicting 30-Day Mortality for Patients With Acute Heart Failure in the Emergency Department. <i>Annals of Internal Medicine</i> , 2018, 168, 899.	3.9	4
182	Triple versus guideline antiplatelet therapy to prevent recurrence after acute ischaemic stroke or transient ischaemic attack: the TARDIS RCT. <i>Health Technology Assessment</i> , 2018, 22, 1-76.	2.8	8
183	Biolimus-A9 polymer-free coated stent in high bleeding risk patients with acute coronary syndrome: a <i>Leaders Free ACS</i> sub-study. <i>European Heart Journal</i> , 2017, 38, ehw203.	2.2	57
184	Sex-related differences in outcomes among men and women under 55 years of age with acute coronary syndrome undergoing percutaneous coronary intervention: Results from the PROMETHEUS study. <i>Catheterization and Cardiovascular Interventions</i> , 2017, 89, 629-637.	1.7	56
185	Comparison of Propensity Score Methods and Covariate Adjustment. <i>Journal of the American College of Cardiology</i> , 2017, 69, 345-357.	2.8	468
186	Longer-term oral antiplatelet use in stable post-myocardial infarction patients: Insights from the long Term risk, clinical management and healthcare Resource utilization of stable coronary artery disease (TIGRIS) observational study. <i>International Journal of Cardiology</i> , 2017, 236, 54-60.	1.7	27
187	International patterns of dual antiplatelet therapy duration after acute coronary syndromes. <i>Heart</i> , 2017, 103, 132-138.	2.9	43
188	Use of prasugrel vs clopidogrel and outcomes in patients with acute coronary syndrome undergoing percutaneous coronary intervention in contemporary clinical practice: Results from the PROMETHEUS study. <i>American Heart Journal</i> , 2017, 188, 73-81.	2.7	25
189	Patterns and associations between DAPT cessation and 2-year clinical outcomes in left main/proximal LAD versus other PCI: Results from the Patterns of Non-Adherence to Dual Antiplatelet Therapy in Stented Patients (PARIS) registry. <i>International Journal of Cardiology</i> , 2017, 243, 132-139.	1.7	11
190	Towards an improved global understanding of treatment and outcomes in people with type 2 diabetes: Rationale and methods of the DISCOVER observational study program. <i>Journal of Diabetes and Its Complications</i> , 2017, 31, 1188-1196.	2.3	46
191	Improving public health by improving clinical trial guidelines and their application. <i>European Heart Journal</i> , 2017, 38, 1632-1637.	2.2	19
192	Association Between Clinical Pathways Leading to Medical Management and Prognosis in Patients With NSTEMI. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2017, 70, 817-824.	0.6	4
193	PREDICTORS OF ISCHEMIC EVENTS WITHIN AND AFTER 1 YEAR AFTER AN ACUTE CORONARY SYNDROME: RESULTS FROM THE EPICOR REGISTRY. <i>Journal of the American College of Cardiology</i> , 2017, 69, 230.	2.8	1
194	Incidence, Patterns, and Associations Between Dual-Antiplatelet Therapy Cessation and Risk for Adverse Events Among Patients With and Without Diabetes Mellitus Receiving Drug-Eluting Stents. <i>JACC: Cardiovascular Interventions</i> , 2017, 10, 645-654.	2.9	17
195	Personalising the decision for prolonged dual antiplatelet therapy: development, validation and potential impact of prognostic models for cardiovascular events and bleeding in myocardial infarction survivors. <i>European Heart Journal</i> , 2017, 38, 1048-1055.	2.2	44
196	New medicinal products for chronic heart failure: advances in clinical trial design and efficacy assessment. <i>European Journal of Heart Failure</i> , 2017, 19, 718-727.	7.1	17
197	Effect of eplerenone in patients with heart failure and reduced ejection fraction: potential effect modification by abdominal obesity. Insight from the <sc>EMPHASIS-HF</sc> trial. <i>European Journal of Heart Failure</i> , 2017, 19, 1186-1197.	7.1	75
198	Characterization of the Average Daily Ischemic and Bleeding Risk After Primary PCI for STEMI. <i>Journal of the American College of Cardiology</i> , 2017, 70, 1846-1857.	2.8	58

#	ARTICLE	IF	CITATIONS
199	Predicting 30-Day Mortality for Patients With Acute Heart Failure in the Emergency Department. <i>Annals of Internal Medicine</i> , 2017, 167, 698.	3.9	152
200	The potential role and rationale for treatment of heart failure with sodium-glucose cotransporter 2 inhibitors. <i>European Journal of Heart Failure</i> , 2017, 19, 1390-1400.	7.1	139
201	White Blood Cell Count and Major Adverse Cardiovascular Events After Percutaneous Coronary Intervention in the Contemporary Era. <i>Circulation: Cardiovascular Interventions</i> , 2017, 10, .	3.9	32
202	Characteristics and outcomes of medically managed patients with non-ST-segment elevation acute coronary syndromes: Insights from the multinational EPICOR Asia study. <i>International Journal of Cardiology</i> , 2017, 243, 15-20.	1.7	15
203	Infections Up to 76 Days After Stroke Increase Disability and Death. <i>Translational Stroke Research</i> , 2017, 8, 541-548.	4.2	25
204	Global geographical variations in ST-segment elevation myocardial infarction management and post-discharge mortality. <i>International Journal of Cardiology</i> , 2017, 245, 27-34.	1.7	91
205	Associations Between Chronic Kidney Disease and Outcomes With Use of Prasugrel Versus Clopidogrel in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention. <i>JACC: Cardiovascular Interventions</i> , 2017, 10, 2017-2025.	2.9	41
206	Challenges in the Design and Interpretation of Noninferiority Trials. <i>Journal of the American College of Cardiology</i> , 2017, 70, 894-903.	2.8	28
207	Normal LDL-Cholesterol Levels Are Associated With Subclinical Atherosclerosis in the Absence of Risk Factors. <i>Journal of the American College of Cardiology</i> , 2017, 70, 2979-2991.	2.8	240
208	Predicting Subclinical Atherosclerosis in Low-Risk Individuals. <i>Journal of the American College of Cardiology</i> , 2017, 70, 2463-2473.	2.8	55
209	Causes, Timing, and Impact of Dual Antiplatelet Therapy Interruption for Surgery (from the Patterns of Tj ETQq1 1 0.784314 rgBT /Over 2017, 120, 904-910.	1.6	10
210	2-Year Outcomes of High-Bleeding-Risk Patients After Polymer-Free Drug-Coated Stents. <i>Journal of the American College of Cardiology</i> , 2017, 69, 162-171.	2.8	109
211	Baseline characteristics of the 3096 patients recruited into the "Triple Antiplatelets for Reducing Dependency after Ischemic Stroke"™ trial. <i>International Journal of Stroke</i> , 2017, 12, 524-538.	5.9	5
212	Impact of proton pump inhibitors and dual antiplatelet therapy cessation on outcomes following percutaneous coronary intervention: Results From the PARIS Registry. <i>Catheterization and Cardiovascular Interventions</i> , 2017, 89, E217-E225.	1.7	13
213	Rationale and design of the long-term risk, clinical management, and healthcare Resource utilization of stable coronary artery disease in post-myocardial infarction patients (TIGRIS) study. <i>Clinical Cardiology</i> , 2017, 40, 1197-1204.	1.8	12
214	Catheter-based renal denervation in patients with uncontrolled hypertension in the absence of antihypertensive medications (SPYRAL HTN-OFF MED): a randomised, sham-controlled, proof-of-concept trial. <i>Lancet, The</i> , 2017, 390, 2160-2170.	13.7	597
215	Intensive versus Guideline Blood Pressure and Lipid Lowering in Patients with Previous Stroke: Main Results from the Pilot "Prevention of Decline in Cognition after Stroke Trial"™ (PODCAST) Randomised Controlled Trial. <i>PLoS ONE</i> , 2017, 12, e0164608.	2.5	60
216	Statistical analysis plan for the "Tranexamic acid for hyperacute primary IntraCerebral Haemorrhage"™ (TICH-2) trial. <i>Trials</i> , 2017, 18, 607.	1.6	15

#	ARTICLE	IF	CITATIONS
217	Time-Dependent Associations Between Actionable Bleeding, Coronary Thrombotic Events, and Mortality Following Percutaneous Coronary Intervention. <i>JACC: Cardiovascular Interventions</i> , 2016, 9, 1349-1357.	2.9	54
218	A win ratio approach to comparing continuous non-normal outcomes in clinical trials. <i>Pharmaceutical Statistics</i> , 2016, 15, 238-245.	1.3	44
219	Statistical Essentials in the Design and Analysis of Clinical Trials. , 2016, , 296-300.		0
220	The Nature of the P Value. <i>New England Journal of Medicine</i> , 2016, 375, 2205-2206.	27.0	7
221	Bleeding Events Before Coronary Angiography in Patients With Non-ST-Segment Elevation Acute Coronary Syndrome. <i>Journal of the American College of Cardiology</i> , 2016, 68, 2608-2618.	2.8	10
222	Prehospital and in-hospital use of healthcare resources in patients surviving acute coronary syndromes: an analysis of the EPICOR registry. <i>Open Heart</i> , 2016, 3, e000347.	2.3	4
223	Analysis of recurrent events with an associated informative dropout time: Application of the joint frailty model. <i>Statistics in Medicine</i> , 2016, 35, 2195-2205.	1.6	41
224	Cryoballoon or Radiofrequency Ablation for Paroxysmal Atrial Fibrillation. <i>New England Journal of Medicine</i> , 2016, 374, 2235-2245.	27.0	1,423
225	Coronary Thrombosis and Major Bleeding After PCI With Drug-Eluting Stents. <i>Journal of the American College of Cardiology</i> , 2016, 67, 2224-2234.	2.8	445
226	Intravenous tranexamic acid for hyperacute primary intracerebral hemorrhage: Protocol for a randomized, placebo-controlled trial. <i>International Journal of Stroke</i> , 2016, 11, 683-694.	5.9	50
227	Assessment of cardiovascular risk of new drugs for the treatment of diabetes mellitus: risk assessment vs. risk aversion. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2016, 2, 200-205.	3.0	30
228	The Primary Outcome Is Positive – Is That Good Enough?. <i>New England Journal of Medicine</i> , 2016, 375, 971-979.	27.0	112
229	Ticagrelor with aspirin or alone in high-risk patients after coronary intervention: Rationale and design of the TWILIGHT study. <i>American Heart Journal</i> , 2016, 182, 125-134.	2.7	108
230	The Primary Outcome Fails – What Next?. <i>New England Journal of Medicine</i> , 2016, 375, 861-870.	27.0	204
231	Association Between a Social-Business Eating Pattern and Early Asymptomatic Atherosclerosis. <i>Journal of the American College of Cardiology</i> , 2016, 68, 805-814.	2.8	24
232	Sex-Based Differences in Cessation of Dual-Antiplatelet Therapy Following Percutaneous Coronary Intervention With Stents. <i>JACC: Cardiovascular Interventions</i> , 2016, 9, 1461-1469.	2.9	37
233	Gender Differences in Associations Between Intraprocedural Thrombotic Events During Percutaneous Coronary Intervention and Adverse Outcomes. <i>American Journal of Cardiology</i> , 2016, 118, 1661-1668.	1.6	6
234	Regression to the Mean in SYMPPLICITY-HTN-3. <i>Journal of the American College of Cardiology</i> , 2016, 68, 2016-2025.	2.8	50

#	ARTICLE	IF	CITATIONS
235	Everolimus-Eluting Stents or Bypass Surgery for Left Main Coronary Artery Disease. <i>New England Journal of Medicine</i> , 2016, 375, 2223-2235.	27.0	843
236	RAPID INTERVENTION WITH GLYCERYL TRINITRATE IN HYPERTENSIVE STROKE TRIAL-2 (RIGHT-2): SAFETY AND EFFICACY OF TRANSDERMAL GLYCERYL TRINITRATE, A NITRIC OXIDE DONOR. <i>Emergency Medicine Journal</i> , 2016, 33, e13.2-e14.	1.0	2
237	Short Telomere Load, Telomere Length, and Subclinical Atherosclerosis. <i>Journal of the American College of Cardiology</i> , 2016, 67, 2467-2476.	2.8	64
238	Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2016, 375, 311-322.	27.0	5,070
239	Aspirin does not reduce the clinical benefits of the mineralocorticoid receptor antagonist eplerenone in patients with systolic heart failure and mild symptoms: an analysis of the <sc>EMPHASIS</sc> study. <i>European Journal of Heart Failure</i> , 2016, 18, 1175-1181.	7.1	12
240	Prediction of 1-year mortality and impact of bivalirudin therapy according to level of baseline risk: A patient-level pooled analysis from three randomized trials. <i>Catheterization and Cardiovascular Interventions</i> , 2016, 87, 391-400.	1.7	8
241	Opportunities for improvement in anti-thrombotic therapy and other strategies for the management of acute coronary syndromes: Insights from EPICOR, an international study of current practice patterns. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2016, 5, 3-12.	1.0	41
242	Oseltamivir for influenza – Authors' reply. <i>Lancet, The</i> , 2016, 387, 125.	13.7	0
243	The rise, fall, and possible resurrection of renal denervation. <i>Nature Reviews Cardiology</i> , 2016, 13, 238-244.	13.7	32
244	The SPYRAL HTN Global Clinical Trial Program: Rationale and design for studies of renal denervation in the absence (SPYRAL HTN OFF-MED) and presence (SPYRAL HTN ON-MED) of antihypertensive medications. <i>American Heart Journal</i> , 2016, 171, 82-91.	2.7	132
245	Incidence and impact of acute kidney injury in patients with acute coronary syndromes treated with coronary artery bypass grafting: Insights from the Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction (HORIZONS-AMI) and Acute Catheterization and Urgent Intervention Triage Strategy (ACUITY) trials. <i>American Heart Journal</i> , 2016, 171, 40-47.	2.7	40
246	Safety and Efficacy of Intensive vs. Guideline Antiplatelet Therapy in High-Risk Patients with Recent Ischemic Stroke or Transient Ischemic Attack: Rationale and Design of the Triple Antiplatelets for Reducing Dependency after Ischaemic Stroke (TARDIS) Trial (ISRCTN47823388). <i>International Journal of Stroke</i> , 2015, 10, 1159-1165.	5.9	24
247	Clinical outcomes according to QRS duration and morphology in the Eplerenone in Mild Patients: Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF). <i>European Journal of Heart Failure</i> , 2015, 17, 707-716.	7.1	16
248	Rationale, Design, and Baseline Characteristics of the <sc>EPICOR</sc> Asia Study (Long-term follow-up of antithrombotic management patterns in Acute Triage of Overlooked Patients)	1.0	0
249	Oseltamivir for influenza – Authors' reply. <i>Lancet, The</i> , 2015, 386, 1135-1136.	13.7	6
250	Baseline characteristics, analysis plan and report on feasibility for the Prevention Of Decline in Cognition After Stroke Trial (PODCAST). <i>Trials</i> , 2015, 16, 509.	1.6	5
251	Differing prognostic value of pulse pressure in patients with heart failure with reduced or preserved ejection fraction: results from the MAGGIC individual patient meta-analysis. <i>European Heart Journal</i> , 2015, 36, 1106-1114.	2.2	53
252	Design of Major Randomized Trials. <i>Journal of the American College of Cardiology</i> , 2015, 66, 2757-2766.	2.8	56

#	ARTICLE	IF	CITATIONS
253	Statistical Controversies in Reporting of Clinical Trials. <i>Journal of the American College of Cardiology</i> , 2015, 66, 2648-2662.	2.8	72
254	Predictors of one-year mortality at hospital discharge after acute coronary syndromes: A new risk score from the EPICOR (long-term follow up of antithrombotic management patterns in acute) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 70: 509-517.	1.0	69
255	Diagnostic and Prognostic Implications of Coronary Flow Capacity. <i>JACC: Cardiovascular Interventions</i> , 2015, 8, 1670-1680.	2.9	87
256	Challenging Issues in Clinical Trial Design. <i>Journal of the American College of Cardiology</i> , 2015, 66, 2886-2898.	2.8	52
257	Does midlife obesity really lower dementia risk? " Authors' reply. <i>Lancet Diabetes and Endocrinology</i> , 2015, 3, 501-502.	11.4	2
258	Bivalirudin Versus Heparin With or Without Glycoprotein IIb/IIIa Inhibitors in Patients With STEMI Undergoing Primary Percutaneous Coronary Intervention. <i>Journal of the American College of Cardiology</i> , 2015, 65, 27-38.	2.8	62
259	Incidence and Impact of Totally Occluded Culprit Coronary Arteries in Patients Presenting With Non-ST-Segment Elevation Myocardial Infarction. <i>American Journal of Cardiology</i> , 2015, 115, 428-433.	1.6	22
260	Effects of long-term use of cardiovascular drugs. <i>Lancet</i> , 2015, 385, 325.	13.7	7
261	Duration of Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation. <i>Journal of the American College of Cardiology</i> , 2015, 65, 1298-1310.	2.8	314
262	Oseltamivir treatment for influenza in adults: a meta-analysis of randomised controlled trials. <i>Lancet</i> , 2015, 385, 1729-1737.	13.7	461
263	Statistical Analysis Plan for the "Triple Antiplatelets for Reducing Dependency after Ischaemic Stroke" (TARDIS) Trial. <i>International Journal of Stroke</i> , 2015, 10, 449-451.	5.9	22
264	10-Year Mortality Outcome of a Routine Invasive Strategy Versus a Selective Invasive Strategy in Non-ST-Segment Elevation Acute Coronary Syndrome. <i>Journal of the American College of Cardiology</i> , 2015, 66, 511-520.	2.8	54
265	Clinical benefits of eplerenone in patients with systolic heart failure and mild symptoms when initiated shortly after hospital discharge: analysis from the EMPHASIS-HF trial. <i>European Heart Journal</i> , 2015, 36, 2310-2317.	2.2	30
266	The perils of surrogate endpoints. <i>European Heart Journal</i> , 2015, 36, 2212-2218.	2.2	61
267	Prevalence, Vascular Distribution, and Multiterritorial Extent of Subclinical Atherosclerosis in a Middle-Aged Cohort. <i>Circulation</i> , 2015, 131, 2104-2113.	1.6	352
268	Prevalence, Impact, and Predictive Value of Detecting Subclinical Coronary and Carotid Atherosclerosis in Asymptomatic Adults. <i>Journal of the American College of Cardiology</i> , 2015, 65, 1065-1074.	2.8	379
269	BMI and risk of dementia in two million people over two decades: a retrospective cohort study. <i>Lancet Diabetes and Endocrinology</i> , 2015, 3, 431-436.	11.4	343
270	Effect of ivabradine on numbers needed to treat for the prevention of recurrent hospitalizations in heart failure patients. <i>Current Medical Research and Opinion</i> , 2015, 31, 1903-1909.	1.9	11

#	ARTICLE	IF	CITATIONS
271	Long-Term Use of Cardiovascular Drugs. Journal of the American College of Cardiology, 2015, 66, 1273-1285.	2.8	111
272	Making Sense of Statistics in Clinical Trial Reports. Journal of the American College of Cardiology, 2015, 66, 2536-2549.	2.8	57
273	Association Between Anthropometry and High Blood Pressure in a Representative Sample of Preschoolers in Madrid. Revista Espanola De Cardiologia (English Ed), 2015, 68, 477-484.	0.6	3
274	Contemporary inter-hospital transfer patterns for the management of acute coronary syndrome patients: Findings from the EPICOR study. European Heart Journal: Acute Cardiovascular Care, 2015, 4, 254-262.	1.0	14
275	VALIDATION OF A QUESTIONNAIRE TO MEASURE OVERALL MEDITERRANEAN LIFESTYLE HABITS FOR RESEARCH APPLICATION: THE MEDITERRANEAN LIFESTYLE INDEX (MEDLIFE). Nutricion Hospitalaria, 2015, 32, 1153-63.	0.3	24
276	Large streamlined trials in cardiovascular disease. European Heart Journal, 2014, 35, 544-548.	2.2	23
277	The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: Guidelines for reporting observational studies. International Journal of Surgery, 2014, 12, 1495-1499.	2.7	5,967
278	Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): Explanation and elaboration. International Journal of Surgery, 2014, 12, 1500-1524.	2.7	1,698
279	Feasibility and Exploratory Efficacy Evaluation of the Embrella Embolic Deflector System for the Prevention of Cerebral Emboli in Patients Undergoing Transcatheter Aortic Valve Replacement. JACC: Cardiovascular Interventions, 2014, 7, 1146-1155.	2.9	127
280	Analysing recurrent hospitalizations in heart failure: a review of statistical methodology, with application to CHARM-Preferred. European Journal of Heart Failure, 2014, 16, 33-40.	7.1	186
281	2014 ESC/ESA Guidelines on non-cardiac surgery: cardiovascular assessment and management. European Heart Journal, 2014, 35, 2383-2431.	2.2	1,253
282	Influence of Hospitalization for Cardiovascular Versus Noncardiovascular Reasons on Subsequent Mortality in Patients With Chronic Heart Failure Across the Spectrum of Ejection Fraction. Circulation: Heart Failure, 2014, 7, 895-902.	3.9	43
283	Long-Term Benefit of Early Pre-Reperfusion Metoprolol Administration in Patients With Acute Myocardial Infarction. Journal of the American College of Cardiology, 2014, 63, 2356-2362.	2.8	162
284	Reduction in Cardiac Mortality With Bivalirudin in Patients With and Without Major Bleeding. Journal of the American College of Cardiology, 2014, 63, 15-20.	2.8	64
285	Individualizing treatment choices using quantitative methods. American Heart Journal, 2014, 168, 607-610.	2.7	10
286	A Polypill Strategy to Improve Adherence. Journal of the American College of Cardiology, 2014, 64, 2071-2082.	2.8	290
287	The percutaneous coronary intervention prior to transcatheter aortic valve implantation (ACTIVATION) trial: study protocol for a randomized controlled trial. Trials, 2014, 15, 300.	1.6	79
288	Do Current Clinical Trials Meet Society's Needs?. Journal of the American College of Cardiology, 2014, 64, 1615-1628.	2.8	53

#	ARTICLE	IF	CITATIONS
289	Effect of Rosuvastatin on Repeat Heart Failure Hospitalizations. <i>JACC: Heart Failure</i> , 2014, 2, 289-297.	4.1	99
290	Current challenges for clinical trials of cardiovascular medical devices. <i>International Journal of Cardiology</i> , 2014, 175, 30-37.	1.7	37
291	Abstract MP38: The Program SI! Intervention for Enhancing a Healthy Lifestyle among Children aged 3 to 5: A Cluster Randomized Trial. <i>Circulation</i> , 2014, 129, .	1.6	0
292	Heart "omics"™ in AGEing (HOMAGE): design, research objectives and characteristics of the common database. <i>Journal of Biomedical Research</i> , 2014, 28, 349.	1.6	24
293	Cessation of dual antiplatelet treatment and cardiac events after percutaneous coronary intervention (PARIS): 2 year results from a prospective observational study. <i>Lancet, The</i> , 2013, 382, 1714-1722.	13.7	537
294	Effect of Early Metoprolol on Infarct Size in ST-Segment" Elevation Myocardial Infarction Patients Undergoing Primary Percutaneous Coronary Intervention. <i>Circulation</i> , 2013, 128, 1495-1503.	1.6	321
295	Learning from recent trials and shaping the future of acute heart failure trials. <i>American Heart Journal</i> , 2013, 166, 629-635.	2.7	30
296	Bivalirudin Started during Emergency Transport for Primary PCI. <i>New England Journal of Medicine</i> , 2013, 369, 2207-2217.	27.0	443
297	Antithrombotic outcome trials in acute coronary syndromes: seeking the optimal balance between safety and efficacy". <i>European Heart Journal</i> , 2013, 34, 1621-1629.	2.2	9
298	Prevention of Decline in Cognition after Stroke Trial (PODCAST): a study protocol for a factorial randomised controlled trial of intensive versus guideline lowering of blood pressure and lipids. <i>Trials</i> , 2013, 14, 401.	1.6	16
299	A win ratio approach to comparing ordinal or non-normal outcomes in clinical trials. <i>Trials</i> , 2013, 14, .	1.6	1
300	International differences in treatment effect: do they really exist and why?". <i>European Heart Journal</i> , 2013, 34, 1846-1852.	2.2	53
301	Predicting survival in heart failure: a risk score based on 39 372 patients from 30 studies. <i>European Heart Journal</i> , 2013, 34, 1404-1413.	2.2	921
302	The impact of eplerenone at different levels of risk in patients with systolic heart failure and mild symptoms: insight from a novel risk score for prognosis derived from the EMPHASIS-HF trial. <i>European Heart Journal</i> , 2013, 34, 2823-2829.	2.2	79
303	Clinical outcome endpoints in heart failure trials: a European Society of Cardiology Heart Failure Association consensus document. <i>European Journal of Heart Failure</i> , 2013, 15, 1082-1094.	7.1	182
304	When to Stop a Clinical Trial Early for Benefit: Lessons Learned and Future Approaches. <i>Circulation: Heart Failure</i> , 2012, 5, 294-302.	3.9	23
305	The win ratio: a new approach to the analysis of composite endpoints in clinical trials based on clinical priorities. <i>European Heart Journal</i> , 2012, 33, 176-182.	2.2	386
306	Ethical Dilemmas and Malfunctions in Clinical Trials Research. <i>Annals of Internal Medicine</i> , 2012, 156, 746.	3.9	9

#	ARTICLE	IF	CITATIONS
307	Reporting of Noninferiority and Equivalence Randomized Trials. JAMA - Journal of the American Medical Association, 2012, 308, 2594.	7.4	1,227
308	Impact of major bleeding and blood transfusions after cardiac surgery: Analysis from the Acute Catheterization and Urgent Intervention Triage strategY (ACUITY) trial. American Heart Journal, 2012, 163, 522-529.	2.7	71
309	The Use of Figures in Epidemiological Publications: A Survey of Current Practice and Consequent Recommendations. , 2012, , 71-83.		1
310	The science of risk models. European Journal of Preventive Cardiology, 2012, 19, 7-13.	1.8	13
311	Transcatheter versus Surgical Aortic-Valve Replacement in High-Risk Patients. New England Journal of Medicine, 2011, 364, 2187-2198.	27.0	5,447
312	Eplerenone in Patients with Systolic Heart Failure and Mild Symptoms. New England Journal of Medicine, 2011, 364, 11-21.	27.0	2,491
313	Heparin plus a glycoprotein IIb/IIIa inhibitor versus bivalirudin monotherapy and paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction (HORIZONS-AMI): final 3-year results from a multicentre, randomised controlled trial. Lancet, The, 2011, 377, 2193-2204.	13.7	421
314	Adaptive increase in sample size when interim results are promising: A practical guide with examples. Statistics in Medicine, 2011, 30, 3267-3284.	1.6	237
315	Authors' response to "Comment on adaptive increase in sample size when interim results are promising" Statistics in Medicine, 2011, 30, 3302-3303.	1.6	3
316	Impact of Bleeding on Mortality After Percutaneous Coronary Intervention. JACC: Cardiovascular Interventions, 2011, 4, 654-664.	2.9	329
317	Categorisation of continuous risk factors in epidemiological publications: a survey of current practice. Epidemiologic Perspectives and Innovations, 2010, 7, 9.	7.0	84
318	Response to Letter Regarding Article, "Prognostic Modeling of Individual Patient Risk and Mortality Impact of Ischemic and Hemorrhagic Complications: Assessment From the Acute Catheterization and Urgent Intervention Triage Strategy Trial". Circulation, 2010, 122, .	1.6	2
319	Baseline characteristics and outcomes of patients with heart failure receiving bronchodilators in the CHARM programme. European Journal of Heart Failure, 2010, 12, 557-565.	7.1	59
320	Prognostic Modeling of Individual Patient Risk and Mortality Impact of Ischemic and Hemorrhagic Complications. Circulation, 2010, 121, 43-51.	1.6	120
321	Randomized Trials, Statistics, and Clinical Inference. Journal of the American College of Cardiology, 2010, 55, 428-431.	2.8	39
322	Long-Term Outcome of a Routine Versus Selective Invasive Strategy in Patients With Non-ST-Segment Elevation Acute Coronary Syndrome. Journal of the American College of Cardiology, 2010, 55, 2435-2445.	2.8	515
323	Transcatheter Aortic-Valve Implantation for Aortic Stenosis in Patients Who Cannot Undergo Surgery. New England Journal of Medicine, 2010, 363, 1597-1607.	27.0	6,189
324	A Risk Score to Predict Bleeding in Patients With Acute Coronary Syndromes. Journal of the American College of Cardiology, 2010, 55, 2556-2566.	2.8	590

#	ARTICLE	IF	CITATIONS
325	Associations of major bleeding and myocardial infarction with the incidence and timing of mortality in patients presenting with non-ST-elevation acute coronary syndromes: a risk model from the ACUITY trial. <i>European Heart Journal</i> , 2009, 30, 1457-1466.	2.2	315
326	Liver function abnormalities and outcome in patients with chronic heart failure: data from the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) program. <i>European Journal of Heart Failure</i> , 2009, 11, 170-177.	7.1	326
327	Ferric Carboxymaltose in Patients with Heart Failure and Iron Deficiency. <i>New England Journal of Medicine</i> , 2009, 361, 2436-2448.	27.0	1,633
328	Paclitaxel-Eluting Stents versus Bare-Metal Stents in Acute Myocardial Infarction. <i>New England Journal of Medicine</i> , 2009, 360, 1946-1959.	27.0	657
329	Translating statistical findings into plain English. <i>Lancet, The</i> , 2009, 373, 1926-1928.	13.7	64
330	Coronary artery bypass surgery compared with percutaneous coronary interventions for multivessel disease: a collaborative analysis of individual patient data from ten randomised trials. <i>Lancet, The</i> , 2009, 373, 1190-1197.	13.7	649
331	Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. <i>Lancet, The</i> , 2009, 373, 2125-2135.	13.7	1,243
332	Insulin glargine and malignancy: an unwarranted alarm. <i>Lancet, The</i> , 2009, 374, 511-513.	13.7	135
333	Angiographic Surrogate End Points in Drug-Eluting Stent Trials. <i>Journal of the American College of Cardiology</i> , 2008, 51, 23-32.	2.8	153
334	The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. <i>Journal of Clinical Epidemiology</i> , 2008, 61, 344-349.	5.0	7,988
335	Impact of hospitalization for acute coronary events on subsequent mortality in patients with chronic heart failure. <i>European Heart Journal</i> , 2008, 30, 338-345.	2.2	26
336	How to interpret figures in reports of clinical trials. <i>BMJ: British Medical Journal</i> , 2008, 336, 1166-1169.	2.3	21
337	Use of Ordinal Outcomes in Vascular Prevention Trials. <i>Stroke</i> , 2008, 39, 2817-2823.	2.0	43
338	Bivalirudin during Primary PCI in Acute Myocardial Infarction. <i>New England Journal of Medicine</i> , 2008, 358, 2218-2230.	27.0	1,693
339	Weight loss and mortality risk in patients with chronic heart failure in the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) programme. <i>European Heart Journal</i> , 2008, 29, 2641-2650.	2.2	164
340	More on Subgroup Analyses in Clinical Trials. <i>New England Journal of Medicine</i> , 2008, 358, 2076-2077.	27.0	28
341	The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: guidelines for reporting observational studies*. <i>Bulletin of the World Health Organization</i> , 2007, 85, 867-872.	3.3	1,159
342	Body Mass Index and Prognosis in Patients With Chronic Heart Failure. <i>Circulation</i> , 2007, 116, 627-636.	1.6	328

#	ARTICLE	IF	CITATIONS
343	Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): Explanation and Elaboration. PLoS Medicine, 2007, 4, e297.	8.4	3,710
344	Routine Upstream Initiation vs Deferred Selective Use of Glycoprotein IIb/IIIa Inhibitors in Acute Coronary Syndromes. JAMA - Journal of the American Medical Association, 2007, 297, 591.	7.4	266
345	Strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. BMJ: British Medical Journal, 2007, 335, 806-808.	2.3	4,798
346	Antithrombotic Strategies in Patients With Acute Coronary Syndromes Undergoing Early Invasive Management. JAMA - Journal of the American Medical Association, 2007, 298, 2497.	7.4	217
347	Sex Differences in Clinical Characteristics and Prognosis in a Broad Spectrum of Patients With Heart Failure. Circulation, 2007, 115, 3111-3120.	1.6	235
348	Influence of Nonfatal Hospitalization for Heart Failure on Subsequent Mortality in Patients With Chronic Heart Failure. Circulation, 2007, 116, 1482-1487.	1.6	528
349	The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: Guidelines for Reporting Observational Studies. Annals of Internal Medicine, 2007, 147, 573.	3.9	5,228
350	Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): Explanation and Elaboration. Annals of Internal Medicine, 2007, 147, W.	3.9	1,339
351	The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement. Epidemiology, 2007, 18, 800-804.	2.7	1,237
352	Strengthening the Reporting of Observational Studies in Epidemiology (STROBE). Epidemiology, 2007, 18, 805-835.	2.7	1,717
353	The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: Guidelines for reporting observational studies. Preventive Medicine, 2007, 45, 247-251.	3.4	887
354	The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet, The, 2007, 370, 1453-1457.	13.7	9,433
355	Safety of drug-eluting stents: demystifying network meta-analysis. Lancet, The, 2007, 370, 2099-2100.	13.7	21
356	Development and validation of a prognostic risk score for major bleeding in patients undergoing percutaneous coronary intervention via the femoral approach. European Heart Journal, 2007, 28, 1936-1945.	2.2	223
357	Red Cell Distribution Width as a Novel Prognostic Marker in Heart Failure. Journal of the American College of Cardiology, 2007, 50, 40-47.	2.8	809
358	The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: Guidelines for Reporting Observational Studies. PLoS Medicine, 2007, 4, e296.	8.4	7,961
359	Figures in clinical trial reports: current practice & scope for improvement. Trials, 2007, 8, 36.	1.6	31
360	Current controversies in data monitoring for clinical trials. Clinical Trials, 2006, 3, 513-521.	1.6	71

#	ARTICLE	IF	CITATIONS
361	The simplest statistical test: how to check for a difference between treatments. <i>BMJ: British Medical Journal</i> , 2006, 332, 1256.	2.3	47
362	Reporting of Noninferiority and Equivalence Randomized Trials. <i>JAMA - Journal of the American Medical Association</i> , 2006, 295, 1152.	7.4	1,027
363	Bivalirudin for Patients with Acute Coronary Syndromes. <i>New England Journal of Medicine</i> , 2006, 355, 2203-2216.	27.0	1,367
364	Clinical Correlates and Consequences of Anemia in a Broad Spectrum of Patients With Heart Failure. <i>Circulation</i> , 2006, 113, 986-994.	1.6	229
365	Predictors of mortality and morbidity in patients with chronic heart failure. <i>European Heart Journal</i> , 2006, 27, 65-75.	2.2	822
366	Eliciting and using expert opinions about influence of patient characteristics on treatment effects: a Bayesian analysis of the CHARM trials. <i>Statistics in Medicine</i> , 2005, 24, 3805-3821.	1.6	25
367	RE: "QUALITY OF REPORTING OF OBSERVATIONAL LONGITUDINAL RESEARCH" <i>American Journal of Epidemiology</i> , 2005, 162, 1032-1033.	3.4	1
368	Data monitoring in randomized controlled trials: surveys of recent practice and policies. <i>Clinical Trials</i> , 2005, 2, 22-33.	1.6	25
369	Risk score for predicting death, myocardial infarction, and stroke in patients with stable angina, based on a large randomised trial cohort of patients. <i>BMJ: British Medical Journal</i> , 2005, 331, 869.	2.3	115
370	The data monitoring experience in the Candesartan in Heart Failure Assessment of Reduction in Mortality and morbidity (CHARM) program. <i>American Heart Journal</i> , 2005, 149, 939-943.	2.7	28
371	When (Not) to Stop a Clinical Trial for Benefit. <i>JAMA - Journal of the American Medical Association</i> , 2005, 294, 2228.	7.4	139
372	Issues in regulatory guidelines for data monitoring committees. <i>Clinical Trials</i> , 2004, 1, 162-169.	1.6	21
373	Issues in the reporting of epidemiological studies: a survey of recent practice. <i>BMJ: British Medical Journal</i> , 2004, 329, 883.	2.3	231
374	The data monitoring experience in the MOXCON trial. <i>European Heart Journal</i> , 2004, 25, 1974-1978.	2.2	32
375	Impact of anemia on outcomes of patients undergoing percutaneous coronary interventions. <i>American Journal of Cardiology</i> , 2004, 94, 1023-1027.	1.6	65
376	A major trial needs three statisticians: why, how and who?. <i>Statistics in Medicine</i> , 2004, 23, 1535-1539.	1.6	23
377	The pros and cons of noninferiority trials. <i>Fundamental and Clinical Pharmacology</i> , 2003, 17, 483-490.	1.9	102
378	Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. <i>Lancet, The</i> , 2003, 362, 759-766.	13.7	1,752

#	ARTICLE	IF	CITATIONS
379	Survival plots of time-to-event outcomes in clinical trials: good practice and pitfalls. <i>Lancet, The</i> , 2002, 359, 1686-1689.	13.7	410
380	Subgroup analysis, covariate adjustment and baseline comparisons in clinical trial reporting: current practice and problems. <i>Statistics in Medicine</i> , 2002, 21, 2917-2930.	1.6	888
381	Accounting For Non-Independent Observations In 2×2 Tables, With Application To Correcting For Family Clustering In Exposure-Risk Relationship Studies. <i>Journal of Modern Applied Statistical Methods</i> , 2002, 1, 379-386.	0.2	1
382	A score for predicting risk of death from cardiovascular disease in adults with raised blood pressure, based on individual patient data from randomised controlled trials. <i>BMJ: British Medical Journal</i> , 2001, 323, 75-81.	2.3	216
383	Randomized clinical trials with added rescue medication: some approaches to their analysis and interpretation. <i>Statistics in Medicine</i> , 2001, 20, 2995-3008.	1.6	28
384	Randomized Trials or Observational Tribulations?. <i>New England Journal of Medicine</i> , 2000, 342, 1907-1909.	27.0	550
385	Subgroup analysis and other (mis)uses of baseline data in clinical trials. <i>Lancet, The</i> , 2000, 355, 1064-1069.	13.7	1,028
386	Evaluation of Antiarrhythmic Drug Efficacy in Patients with an ICD:.. <i>Journal of Cardiovascular Electrophysiology</i> , 1999, 10, 1534-1549.	1.7	6
387	Trials stopped early: too good to be true?. <i>Lancet, The</i> , 1999, 353, 943-944.	13.7	103
388	The agonising negative trend in monitoring of clinical trials. <i>Lancet, The</i> , 1999, 354, 1983-1988.	13.7	129
389	The hope and the hazards of using compliance data in randomized controlled trials. , 1998, 17, 303-317.		56
390	The hope and the hazards of using compliance data in randomized controlled trials. <i>Statistics in Medicine</i> , 1998, 17, 303-317.	1.6	1
391	Linearly divergent treatment effects in clinical trials with repeated measures: efficient analysis using summary statistics. <i>Statistics in Medicine</i> , 1997, 16, 2855-2872.	1.6	49
392	STATISTICAL REPORTING OF CLINICAL TRIALS WITH INDIVIDUAL CHANGES FROM ALLOCATED TREATMENT. , 1996, 15, 249-262.		35
393	THE ROLE OF EXTERNAL EVIDENCE IN DATA MONITORING OF A CLINICAL TRIAL. , 1996, 15, 1285-1293.		12
394	STATISTICAL REPORTING OF CLINICAL TRIALS WITH INDIVIDUAL CHANGES FROM ALLOCATED TREATMENT. <i>Statistics in Medicine</i> , 1996, 15, 249-262.	1.6	1
395	Life as an academic medical statistician and how to survive it. <i>Statistics in Medicine</i> , 1995, 14, 209-222.	1.6	12
396	Optimal Sequential Screening Guidelines for Quantitative Risk Factors Measured with Error. <i>Journal of the American Statistical Association</i> , 1995, 90, 19-26.	3.1	5

#	ARTICLE	IF	CITATIONS
397	Repeated measures in clinical trials: Analysis using mean summary statistics and its implications for design. <i>Statistics in Medicine</i> , 1994, 13, 197-198.	1.6	176
398	Statistical and ethical issues in monitoring clinical trials. <i>Statistics in Medicine</i> , 1993, 12, 1459-1469.	1.6	74
399	Repeated measures in clinical trials: Analysis using mean summary statistics and its implications for design. <i>Statistics in Medicine</i> , 1992, 11, 1685-1704.	1.6	563
400	Prediction of short-term survival with an application in primary biliary cirrhosis. <i>Statistics in Medicine</i> , 1992, 11, 1731-1745.	1.6	33
401	Estimation issues in clinical trials and overviews. <i>Statistics in Medicine</i> , 1990, 9, 657-671.	1.6	84
402	Statistical Problems in the Reporting of Clinical Trials. <i>New England Journal of Medicine</i> , 1987, 317, 426-432.	27.0	668
403	Interim Analyses in Randomized Clinical Trials: Ramifications and Guidelines for Practitioners. <i>Biometrics</i> , 1987, 43, 213.	1.4	178
404	Statistical Essentials in the Design and Analysis of Clinical Trials. , 0, , 491-501.		0